Drug Trial Radar · NCT02666664
Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)
Last checked: Nov 20, 2026Latest source record: May 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,230
Actual
Start
Jan 21, 2016
Primary completion
Feb 21, 2018
Study completion Mar 28, 2018
Sponsor
- Lead sponsor
- Esperion Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to see if ETC-1002 (bempedoic acid) is safe and well-tolerated versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.
Conditions
- Hypercholesterolemia
- Atherosclerotic Cardiovascular Diseases
Interventions
ETC-1002Drug
ETC-1002 180 mg tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
PlaceboDrug
Matching placebo tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to approximately 52 weeks
- Percentage of Participants With Adjudicated Major Adverse Cardiovascular EventTime frame: Up to approximately 52 weeks
- Percentage of Participants With the Indicated Event of Special Interest: Creatine Kinase ElevationsTime frame: Up to approximately 52 weeks
- Percentage of Participants With the Indicated Event of Special Interest: Hepatic DisordersTime frame: Up to approximately 52 weeks
- Percentage of Participants With the Indicated Event of Special Interest: HypoglycemiaTime frame: Up to approximately 52 weeks
- Percentage of Participants With the Indicated Event of Special Interest: Metabolic AcidosisTime frame: Up to approximately 52 weeks
- Percentage of Participants With the Indicated Event of Special Interest: Muscular DisorderTime frame: Up to approximately 52 weeks
- Percentage of Participants With the Indicated Event of Special Interest: Neurocognitive DisorderTime frame: Up to approximately 52 weeks
- Percentage of Participants With the Indicated Event of Special Interest: New Onset or Worsening Diabetes MellitusTime frame: Up to approximately 52 weeks
- Percentage of Participants With the Indicated Event of Special Interest: Renal DisorderTime frame: Up to approximately 52 weeks
- Change From Baseline to Week 52 in Uric Acid (Urate) LevelTime frame: Baseline and Week 52
- Change From Baseline to Week 52 in Creatinine LevelTime frame: Baseline and Week 52
- Change From Baseline to Week 52 in Hemoglobin LevelTime frame: Baseline and Week 52
Locations
104 sites in 6 countries. Site status is shown where the registry gives one.
Site not named
Huntsville, Alabama
Site not named
Cottonwood, Arizona
Site not named
Phoenix, Arizona
Site not named
Canoga Park, California
Site not named
Santa Rosa, California
Site not named
Bridgeport, Connecticut
Site not named
Hartford, Connecticut
Site not named
Atlantis, Florida
Site not named
Boca Raton, Florida
Site not named
Crestview, Florida
Site not named
Crystal River, Florida
Site not named
Daytona Beach, Florida
Site not named
Lake Worth, Florida
Site not named
Miami Lakes, Florida
Site not named
Tampa, Florida
Site not named
Park Ridge, Illinois
Site not named
Iowa City, Iowa
Site not named
Overland Park, Kansas
Site not named
Covington, Kentucky
Site not named
Louisville, Kentucky
Site not named
Minden, Louisiana
Site not named
Monroe, Louisiana
Site not named
Shreveport, Louisiana
Site not named
Auburn, Maine
Site not named
Midland, Michigan
Site not named
Saginaw, Michigan
Site not named
Saint Cloud, Minnesota
Site not named
Tupelo, Mississippi
Site not named
Jefferson City, Missouri
Site not named
Nashua, New Hampshire
Site not named
Bridgewater, New Jersey
Site not named
Cary, North Carolina
Site not named
Mount Airy, North Carolina
Site not named
Raleigh, North Carolina
Site not named
Rocky Mount, North Carolina
Site not named
Wilmington, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Sandusky, Ohio
Site not named
Willoughby, Ohio
Site not named
Hillsboro, Oregon
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.